Search results
Results from the WOW.Com Content Network
Levamlodipine , also known as levoamlodipine or S-amlodipine is a pharmacologically active enantiomer of amlodipine. [1] Amlodipine belongs to the dihydropyridine group of calcium channel blocker used as an antihypertensive and antianginal agent. [2] It was approved by the U.S. FDA in December 2019 and is currently marketed under the brand name ...
Although the mechanism is unclear, increased insulin may mobilize glucose from peripheral tissues to serve as an alternative fuel source for the heart (the heart mainly relies on oxidation of fatty acids). Theoretical treatment with lipid emulsion therapy has been considered in severe cases, but is not yet standard of care.
In the VALUE trial, the ARB valsartan produced a statistically significant 19% (p=0.02) relative increase in the prespecified secondary end point of myocardial infarction (fatal and non-fatal) compared with amlodipine. [25] The CHARM-alternative trial showed a significant +52% (p=0.025) increase in myocardial infarction with candesartan (versus ...
A widower has called for health boards to halt the use of Omnipod insulin pumps, as he fears one malfunctioned and killed his husband. Paul McNairney, 39, died last month after the Omnipod ...
The Tandem Diabetes Care t:Slim X2 was approved by the U.S. Food and Drug Administration in 2019 and is the first insulin pump to be designated as an alternate controller enabled (ACE) insulin pump. ACE insulin pumps allow users to integrate continuous glucose monitors, automated insulin dosing (AID) systems, and other diabetes management ...
Eggs. In 2020, eggs were just $1.45 and this year, they're $3.00. If this seems extreme to you, you haven't been paying attention. Last year, a dozen eggs went for $4.82, suggesting a pretty ...
Insulin pumps, cartridges, and infusion sets may be far more expensive than syringes used for insulin injection with several insulin pumps costing more than $6,000; necessary supplies can cost over $300. [3] Another disadvantage of insulin pump use is a higher risk of developing diabetic ketoacidosis if the pump malfunctions. [3]
Insulin device maker Insulet Corporation (NASDAQ:PODD) reported a second-quarter adjusted EPS of $0.55 on Thursday, missing the consensus estimate of $0.56. It reported an EPS of $0.38 a year ago.